CBD and Depression

Peer-reviewed studies into the potential effects of Cannabidiol and Depression

On this page, CBD and Depression, you will find research pertaining to the use of Cannabidiol and Cannabinoids and its possible effects on Depression. The information below is not meant to influence your opinion, but rather give you access to a wealth of scientific literature in an attempt to make and educated and informed choice. Click Here to see all of the conditions that have been researched alongside CBD and Depression.

Endocannabinoid system dysfunction in mood and related disorders.

From the abstract:

We propose (hypothesize) that the [endocannabinoid] system, which is homoeostatic in cortical excitation and inhibition, is dysfunctional in mood and related disorders. Anandamide, tetrahydrocannabinol (THC) and cannabidiol (CBD) variously combine antidepressant, antipsychotic, anxiolytic, analgesic, anticonvulsant actions, suggesting a therapeutic potential in mood and related disorders. 

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of cannabis sativa.

From the abstract:

Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound… Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed.

The endocannabinoid system and the treatment of mood and anxiety disorders.  

From the abstract:

A growing body of evidence unequivocally demonstrates that deficits in endocannabinoid signalling may result in depressive and anxiogenic behavioral responses, while pharmacological augmentation of endocannabinoid signalling can produce both antidepressive and anxiolytic behavioral responses..Collectively, both clinical and preclinical data argue that cannabinoid receptor signalling may be a realistic target in the development of a novel class of agent for the pharmacotherapy of mood and anxiety disorders.

Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness

From the abstract:

Together the available data indicate that activators of CB1 [receptor] signaling, particularly inhibitors of fatty acid amide hydrolase, should be considered for clinical trials for the treatment of depression..

Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

From the abstract:

CBD induces antidepressant-like effects comparable to those of imipramine. These effects of CBD were probably mediated by activation of 5-HT(1A) receptors.

Putative role of the endocannabinoid signaling in the etiology of depression and actions of antidepressants.

From the abstract:

Ultimately, these data present a compelling picture of the putative role of the endocannabinoid system in the processes subserving both the development and treatment of depression.

Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

From the abstract:

Results of this study show that Delta(9)-THC and other cannabinoids exert antidepressant-like actions, and thus may contribute to the overall mood-elevating properties of cannabis.

Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social-stress.

From the abstract:

Central endocannabinoid signaling is known to be responsive to stressful stimuli; however, there is no research to date characterizing the effects of stress on peripheral endocannabinoid content..These are the first data to demonstrate that the peripheral endocannabinoid/NAE system is responsive to exposure to stress.

Serum contents of endocannabinoids are correlated with blood pressure in depressed women.

From the abstract:

This preliminary study raises the possibility that endocannabinoids play a role in blood pressure regulation in depressives with higher blood pressure, and suggests an interrelationship among endocannabinoids, depression and cardiovascular risk factors in women.

The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants.

From the abstract:

These preclinical findings support the rationale for the clinical development of agents which inhibit the cellular uptake and/or metabolism of endocannabinoids in the treatment of mood disorders.

Anti-depressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures.

From the abstract:

The endocannabinoid (eCB) system has recently been implicated in both the pathogenesis of depression and the action of antidepressants..the eCB system appears to play a significant role in the mechanism of action of clinically effective and potential antidepressants and may serve as a target for drug design and discovery.

Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.

From the abstract:

Cannabidiol (CBD), the main non-psychotomimetic component of marihuana, exhibits anxiolytic-like properties in many behavioural tests, although its potential for treating major depression has been poorly explored..our findings indicate that CBD could represent a novel fast antidepressant drug, via enhancing both serotonergic and glutamate cortical signalling through a 5-HT1A receptor-dependent mechanism.

Prohedonic Effects of Cannabidiol in a Rat Model of Depression.

From the abstract:

Accumulating evidence suggests that cannabidiol (CBD) may be an effective and safe anxiolytic agent and potentially also an antidepressant..These findings extend the limited knowledge on the antidepressant effect of CBD, now shown for the first time in a genetic animal model of depression. These results suggest that CBD may be beneficial for the treatment of clinical depression and other states with prominent anhedonia.

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

From the abstract:

Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound..Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed.